Premium
Reverse Use Dependence of Antiarrhythmic Class la, Ib, and Ic: Effects of Drugs on the Action Potential Duration?
Author(s) -
LANGENFELD HEINER,
KÖHLER CHRISTIANE,
WEIRICH JÖRG,
KIRSTEIN MICHAEL,
KOCHSIEK KURT
Publication year - 1992
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.1992.tb03028.x
Subject(s) - quinidine , medicine , atrium (architecture) , ventricle , repolarization , cardiology , antiarrhythmic agent , propafenone , anti arrhythmia agents , stimulation , flecainide , electrophysiology , heart disease , atrial fibrillation
The prolongation of the action potential duration (APD) induced by sotalol has been shown to be diminished with increasing heart rate. This phenomenon is called “reverse use dependence.” We examined the la, Ib, and Ic effects of different Class I drugs on the APD under normal and fast stimulation rates (1.0 and 2.5 Hz) in isolated rabbit atria) and ventricular muscles by means of intracelular microelectrodes. Results (n = 98): With 1.0 Hz lidocaine fib, 4.3 ? 10 −5 M) shortened the APD at 90% repolarization (APD90) in the atrium by 9% and in the ventricle lay 8% (NS), whereas quinidine (la, 2.2 ? 10 −5 M) and prajmaline (la, 10 −6 M) prolonged the APD90 in the atrium (quinidine +45%; prajmaline +10%, P < 0.001) and in the ventricle (+ 42%, P < 0.001; +17%, P < 0.05J. Propafenone (Ic, 2.6 ? 10 −6 M) showed this effect only in the atrium (APD90 + 33%; P < 0.01). With the faster stimulation rate of 2.5 Hz we could not find a significant influence of any drug on the APD90 in the ventricle and only quinidine prolonged the APD90 in the atrium by 16% (P < 0.05). Conclusions: The subclassification of Class I antiarrhythmic drugs that is based on APD modifying influences is only valid under normal heart rates (1.0 Hz). During tachycardia these actions are absent and the phenomenon of “reverse use dependence” is found in Class I drugs. Therefore, an additional antiarrhythmic effect due to APD modification by the examined drugs should not be expected at rapid heart rates.